Global disparities in SARS-CoV-2 genomic surveillance
Yale University · Instituto de Saúde · +54 more institutions
Abstract
Genomic sequencing is essential to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments, vaccines, and guide public health responses. To investigate the global SARS-CoV-2 genomic surveillance, we used sequences shared via GISAID to estimate the impact of sequencing intensity and turnaround times on variant detection in 189 countries. In the first two years of the pandemic, 78% of high-income countries sequenced >0.5% of their COVID-19 cases, while 42% of low- and middle-income countries reached that mark. Around 25% of the genomes from high income countries were submitted within 21 days, a pattern observed in 5% of the genomes from low- and middle-income countries. We found that…
Citation impact
- FWCI
- 25.10
- Percentile
- 100%
- References
- 49
Authors
212Topics & keywords
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Sars virus
- Coronavirus disease 2019 (COVID-19)
- 2019-20 coronavirus outbreak
- Virology
- Pandemic
- Betacoronavirus
- Computational biology
Funding
- BABill and Melinda Gates FoundationAwards: INV-034540 and INV-034652, INV-034540, INV-034652
- RFRockefeller Foundation
- GMGeorge Mason University
- WTWellcome TrustAwards: 220414/Z/20/Z, 204311/Z/16/Z, G0E1420N, C14/18/094
- ECEuropean CommissionAwards: EDCTP2, EDCTP2 programme
- FDFundação de Amparo à Pesquisa do Estado de São PauloAwards: 307145/2021-2, FAPESP 18/14389-0, 18/14389-0
- CDCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
- MDMinisterio de Economía y Competitividad
- MDMinistério da Ciência, Tecnologia e InovaçãoAward: 0494/20
- CNConselho Nacional de Desenvolvimento Científico e TecnológicoAwards: 439119/2018-9, 307145/2021-2, 312688/2017-2 and 439119/2018-9, 404096/2020-4, 312688/2017-2, 440931/2020-7, 404096/2020, 2017-2, 01.20.0029.000462/20
- KLKU LeuvenAward: C14/18/094
- FCFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de JaneiroAwards: E-26/, E-26/210, E-26/210.179/2020, E-26/211, 202.922/2018, E-26/211.107/2021, 307145/2021-2
- FDFinanciadora de Estudos e ProjetosAwards: 1139/20, 404096/2020-4, 0494/20, 01.20.0029.000462/20, 0494/20 01.20.0026.00
- UFUniversidade Federal de Minas Gerais
- VRVlaamse regering
- FCForeign, Commonwealth and Development Office
- NINational Institutes of HealthAwards: F31 AI154824, U19 AI135995, AI154824, AI135995, AI153044, NIH R01, R01 AI153044
- CFCenters for Disease Control and PreventionAward: 75D30120C09570
- MCMercatus Center, George Mason University
- MRMedical Research CouncilAwards: FAPESP 18/14389-0, MR/R015600/1, MR/S019510/1
- EAEngineering and Physical Sciences Research CouncilAwards: EP/V002910/1, EP/V002910/1
- EAEuropean and Developing Countries Clinical Trials PartnershipAward: EDCTP2